Osaic Holdings’s Evogene EVGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44 Hold
100
﹤0.01% 7879
2026
Q1
$77 Sell
100
-50
-33% -$47 ﹤0.01% 7652
2025
Q4
$149 Sell
150
-40
-21% -$47 ﹤0.01% 7611
2025
Q3
$240 Hold
190
﹤0.01% 7673
2025
Q2
$244 Hold
190
﹤0.01% 7475
2025
Q1
$242 Sell
190
-350
-65% -$528 ﹤0.01% 7140
2024
Q4
$1.08K Hold
540
﹤0.01% 6823
2024
Q3
$1.58K Hold
540
﹤0.01% 6699
2024
Q2
$3.4K Sell
540
-303
-36% -$2.12K ﹤0.01% 6360
2024
Q1
$6.32K Hold
843
﹤0.01% 5979
2023
Q4
$7.08K Hold
843
﹤0.01% 6008
2023
Q3
$4.94K Sell
843
-50
-6% -$438 ﹤0.01% 6278
2023
Q2
$9.59K Hold
893
﹤0.01% 5992
2023
Q1
$5.61K Hold
893
﹤0.01% 6269
2022
Q4
$6K Hold
893
﹤0.01% 6191
2022
Q3
$7K Hold
893
﹤0.01% 6183
2022
Q2
$6K Buy
893
+150
+20% +$1.47K ﹤0.01% 6375
2022
Q1
$10K Hold
743
﹤0.01% 6118
2021
Q4
$12K Hold
743
﹤0.01% 6134
2021
Q3
$20K Buy
743
+53
+8% +$1.55K ﹤0.01% 5766
2021
Q2
$23K Hold
690
﹤0.01% 5566
2021
Q1
$35K Buy
690
+650
+1,625% +$40.2K ﹤0.01% 5125
2020
Q4
$2K Buy
40
+5
+14% +$176 ﹤0.01% 6060
2020
Q3
$1K Buy
35
+7
+25% +$125 ﹤0.01% 5999
2020
Q2
$0 Buy
28
+26
+1,300% +$282 ﹤0.01% 6167
2020
Q1
$0 Buy
+2
New +$28 ﹤0.01% 6098

Other funds holding EVGN

Osaic Holdings's EVGN Position: Q2 2026 in Review

Osaic Holdings held its Evogene (EVGN) position steady in Q2 2026 at 100 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #7879.

Osaic Holdings first reported a position in EVGN in Q1 2020 and has held it in 26 quarters since. The position peaked at $35K in Q1 2021. 13 funds tracked by Wall St. Rank hold EVGN as of Q2 2026.

  • Osaic Holdings held 100 shares of Evogene worth $44 as of Q2 2026.
  • Osaic Holdings left its Evogene share count unchanged in Q2 2026.
  • Evogene made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7879 holding.
  • Osaic Holdings first reported a position in Evogene in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Evogene position peaked at $35K in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Evogene as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.